Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: Results from the LRF CLL4 trial

Journal of Clinical Oncology

Volumn 29, Issue 16, 2011, Pages 2223-2229

  Gonzalez, David ^a,b,c   Martinez, Pilar ^a,b,c   Wade, Rachel ^a,b,c   Hockley, Sarah ^a,b,c   Oscier, David ^a,b,c   Matutes, Estella ^a,b,c   Dearden, Claire E ^a,b,c   Richards, Sue M ^a,b,c   Catovsky, Daniel ^a,b,c   Morgan, Gareth J ^a,b,c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^c ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; PROTEIN KINASE ZAP 70; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHROMOSOME DELETION 13; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; EXON; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TREATMENT RESPONSE; TRISOMY 12;

ANTINEOPLASTIC AGENTS; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DNA MUTATIONAL ANALYSIS; GENES, P53; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; VIDARABINE;

EID: 79957949229     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.0838     Document Type: Article

References (29)

1. Döhner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000
2. Stilgenbauer S, Bullinger L, Lichter P, et al: Genetics of chronic lymphocytic leukemia: Genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 16:993-1007, 2002 (Pubitemid 34618838)
3. Hamblin TJ, Davis Z, Gardiner A, et al: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999
4. Damle RN, Wasil T, Fais F, et al: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999
5. Crespo M, Bosch F, Villamor N, et al: ZAP-70 expression as a surrogate for immunoglobulinvariable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764-1775, 2003 (Pubitemid 36514707)
6. Rassenti LZ, Jain S, Keating MJ, et al: Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112:1923-1930, 2008
7. Kröber A, Bloehdorn J, Hafner S, et al: Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 24:969-975, 2006 (Pubitemid 46646223)
8. Zenz T, Kröber A, Scherer K, et al: Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term follow-up. Blood 112:3322-3329, 2008
9. Oscier DG, Gardiner AC, Mould SJ, et al: Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100:1177-1184, 2002
10. Döhner H, Fischer K, Bentz M, et al: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580-1589, 1995
11. Byrd JC, Gribben JG, Peterson BL, et al: Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 24:437-443, 2006 (Pubitemid 46655595)
12. Oscier D, Wade R, Davis Z, et al: Prognostic factors identify three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 95:1705-1712, 2010
13. Song H, Xu Y: Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways. Cell Cycle 6:1570-1573, 2007 (Pubitemid 47327942)
14. Riley T, Sontag E, Chen P, et al: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9:402-412, 2008
15. Dicker F, Herholz H, Schnittger S, et al: The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 23:117-124, 2009
16. Rossi D, Cerri M, Deambrogi C, et al: The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: Implications for overall survival and chemorefractoriness. Clin Cancer Res 15:995-1004, 2009
17. Zenz T, Häbe S, Denzel T, et al: Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): Dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114:2589-2597, 2009
18. Zenz T, Benner A, Döhner H, et al: Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway. Cell Cycle 7:3810-3814, 2008
19. Grever MR, Lucas DM, Dewald GW, et al: Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25:799-804, 2007 (Pubitemid 350010635)
20. Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 370:230-239, 2007 (Pubitemid 47069536)
21. International Agency on Research for Cancer (IARC): IARC TP53 Database. http://www-p53.iarc.fr
22. The TP53 Web Site. http://p53.free.fr/index.html
23. Stilgenbauer S, Zenz T, Winkler D, et al: Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27:3994-4001, 2009
24. Malcikova J, Smardova J, Rocnova L, et al: Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: Selection, impact on survival, and response to DNA damage. Blood 114:5307-5314, 2009
25. Zenz T, Eichhorst B, Busch R, et al: TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28:4473-4479, 2010
26. Best OG, Gardiner AC, Davis ZA, et al: A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia 23:212-214, 2009
27. Tam CS, Shanafelt TD, Wierda WG, et al: De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: The M. D. Anderson and Mayo Clinic experience. Blood 114:957-964, 2009
28. Tsimberidou AM, Tam C, Abruzzo LV, et al: Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 115:373-380, 2009
29. Zenz T, Hoth P, Busch R, et al: Impact of TP53 mutations on outcome: Results from the CLL8 trial (FC VS. R-FC) of the GCLLSG. Haematologica 95:223, 2010 (abstr 0543)